Among VEGF or VEGF receptor targeting monoclonal antibodies, aflibercept has been associated with an increased incidence of hypertension in comparison to bevacizumab and ramucirumab in the treatment of metastatic colorectal cancer [13]. The gene discussed is VEGFA; the disease is hypertensive disorder.